Jiménez-López Julia, García-Hevia Lorena, Melguizo Consolación, Prados Jose, Bañobre-López Manuel, Gallo Juan
Institute of Biopathology and Regenerative Medicine (IBIM9090325ER), Center of Biomedical Research (CIBM), University of Granada, 18014 Granada, Spain.
Department of Anatomy and Embryology, Faculty of Medicine, University of Granada, 18014 Granada, Spain.
Pharmaceutics. 2020 Jul 7;12(7):637. doi: 10.3390/pharmaceutics12070637.
The development of nanotechnology-based solutions for cancer at a preclinical level advances at an astounding pace. So far, clinical translation of these new developments has not been able to keep the pace due to a range of different reasons. One of them is the mismatch between in vitro and in vivo results coming from the expected difference in complexity. To overcome this problem, extensive characterisation using advanced in vitro models can lead to stronger preliminary data to face in vivo tests. Here, a comprehensive in vitro validation of a combinatorial therapy nanoformulation against solid tumours is presented. The information extracted from the different in vitro models highlights the importance of advanced 3D models to fully understand the potential of this type of complex drugs.
基于纳米技术的癌症临床前解决方案正以惊人的速度发展。到目前为止，由于一系列不同的原因，这些新进展的临床转化未能跟上步伐。其中一个原因是体外和体内结果之间的不匹配，这源于预期的复杂性差异。为了克服这个问题，使用先进的体外模型进行广泛的表征可以产生更强有力的初步数据来面对体内测试。在此，展示了一种针对实体瘤的联合治疗纳米制剂的全面体外验证。从不同体外模型中提取的信息突出了先进的3D模型对于充分理解这类复杂药物潜力的重要性。
